Noul Co

Noul Co EBIT Margin

The EBIT Margin (Operating Margin) of Noul Co (376930.KQ) as of Oct 31, 2026 is -392.03 %. In the previous year, EBIT Margin (Operating Margin) was -1,423.37 % — a change of -72.46% (higher).

EBIT Margin

-392.03 %

YoY

-72.46%

Last updated:

EBIT Margin (Operating Margin) of Noul Co is 2025 -392.03 % . EBIT Margin (Operating Margin) of Noul Co was 2024 -1,423.37 % . It decreases by -72.46% higher compared to the previous year.

Noul Co's operating (EBIT) margin stands at -392.0%, up from -775.3% several years earlier.

The Noul Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2020
-2,761.59 KRW
Jan 1, 2021
-775.29 KRW
Jan 1, 2022
-2,884.82 KRW
Jan 1, 2023
-590.33 KRW
Jan 1, 2024
-1,423.37 KRW
Jan 1, 2025
-392.03 KRW
The Noul Co EBIT Margin history
YEAREBIT MarginYoY
-392.03 %-72.46%
-1,423.37 %+141.11%
-590.33 %-79.54%
-2,884.82 %+272.10%
-775.29 %-71.93%
-2,761.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Noul Co Stock analysis

What does Noul Co do? Noul Co., Ltd. generates revenue through the manufacture and sale of blood test diagnostic devices utilizing AI algorithms and diagnostic kits. The company offers regular monthly subscriptions via its integrated web-based remote diagnosis system, targeting healthcare providers and medical facilities seeking advanced diagnostic solutions. Its core products include AI-based diagnostic devices and associated kits, sold directly to clinics and hospitals for use in blood testing procedures. The firm's services are designed to enhance diagnostic accuracy and efficiency through remote access and subscription models. The company's primary revenue streams stem from the sale of physical diagnostic devices and diagnostic kits, alongside recurring subscription fees for its web-based remote diagnosis platform. Healthcare institutions and medical professionals form the key customer segments, purchasing both the hardware and ongoing service access. Noul Co., Ltd. focuses on delivering AI-driven diagnostic tools that integrate seamlessly into existing healthcare workflows, emphasizing convenience and technological innovation for its clients. Noul Co., Ltd. operates exclusively within the healthcare diagnostics sector, providing AI-powered blood test solutions that combine hardware sales with subscription-based software services. The business model relies on initial device purchases followed by continuous revenue from monthly subscriptions, creating a sustainable income stream. This approach ensures long-term engagement with healthcare providers while maintaining a focus on cutting-edge diagnostic technology. Noul Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Noul Co stock

EBIT Margin (Operating Margin) of Noul Co is -392.03 % in 2025.

EBIT Margin (Operating Margin) of Noul Co changed from -1,423.37 % to -392.03 %, representing a -72.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Noul Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Noul Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Noul Co

All Key Metrics — Noul Co